
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx is attractive because izicopan appears to combine a validated C5aR mechanism with a meaningfully better product profile than Tavneos, including faster pharmacology, no SAEs or TEAEs in more than 180 subjects, and simpler dosing. The opportunity is amplified by Tavneos’ commercial success, with $643M in 2025 worldwide AAV sales, alongside mounting regulatory and safety concerns, including FDA-cited 76 DILI cases and proposed withdrawal, which could open share for a safer alternative. Financially, the company ended 2Q26 with no debt and about €158M cash, and its pipeline also offers upside through renal indications and partnering optionality if izicopan’s upcoming studies continue to validate the thesis.
Bears say
InflaRx is a high-risk biopharma with weak current commercial traction, as GOHIBIC/vilobelimab has been effectively wound down in active U.S. commercialization and the company booked only about €29K of revenue against roughly €18.0M of SG&A expense in 2025, underscoring a severe mismatch between spend and sales. Its long-term value depends heavily on partnership-driven development and uncertain clinical expansion, while even promising opportunities such as AAV face entrenched approved competitors and a need for meaningful differentiation and commercial infrastructure that InflaRx lacks. The outlook is further pressured by expected losses for several years, likely additional capital needs, and unresolved legal and patent risks, any of which could dilute shareholders or limit the company’s ability to protect and monetize its pipeline.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About InflaRx (IFRX) Forecast
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares